Recently, one of the most influential professional media in the international pharmaceutical technology field, "Pharma Tech Outlook," officially announced the annual list of "TOP PRECLINICAL RESEARCH SERVICES 2025." Laviana Pharma stood out from global candidates due to its strong foundation, innovative breakthroughs, and excellent customer reputation in the field of preclinical research services, winning the award.

As one of the most influential professional media in the international pharmaceutical technology field, Pharma Tech Outlook has over 36.000 high-quality print circulation and 70.000 digital subscribers in the Asia-Pacific region. The magazine focuses on providing the most valuable professional content for executives in pharmaceutical companies, technology research and development experts, and industry decision-makers. It covers core sections such as analysis of cutting-edge trends in pharmaceutical technology, innovative case studies of product services, evaluation of global quality suppliers, and sharing of experiences from industry leaders. By inviting executives from multinational pharmaceutical companies, scholars from top research institutions, and authoritative experts in the industry to contribute articles, it builds a communication bridge between technological innovation and industrial application. Each issue undergoes a rigorous editorial process to ensure professionalism and authority.

Since its establishment, Laviana Pharma has formed an open technology platform covering the entire process of innovative drugs through continuous innovation and technological upgrades, possessing multiple invention patents in asymmetric synthesis, continuous flow reactions, and more. With its independently developed innovative technology platform, efficient experimental process management, and deep understanding of international regulatory standards, it continuously provides high-quality, customized solutions for global clients, helping to accelerate multiple collaborative projects to the clinical stage and playing a key role in the global pharmaceutical R&D industry chain. As of now, Laviana Pharma has served over 300 well-known pharmaceutical companies both domestically and internationally, completing thousands of process R&D projects, and helping global partners effectively shorten the new drug development cycle and reduce R&D costs.

This prestigious international award not only represents a high recognition of Laviana Pharma's outstanding comprehensive strength but also marks an important milestone in its journey to becoming a flagship enterprise in the professional CDMO field. In the context of the ongoing global wave of pharmaceutical innovation, Laviana Pharma will continue to adhere to innovation as its engine, deepen the construction of its R&D system, optimize its full-process service capabilities, and provide more valuable end-to-end solutions for partners by building a global strategic cooperation network.